AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03865992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given capsules for oral administration
Study NCT03865992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanoemulsion
Description: Given nanoemulsion curcumin PO
Study NCT03865992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03865992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT02899442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collective prevention in workplace
Description: From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
Study NCT03564535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self fixating group
Description: Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11\*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
Study NCT03564535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tacker fixation group
Description: Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
Study NCT06537284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImRs-DSR
Description: Imagery Rescripting with Memory Reconsolidation Disruption
Study NCT06537284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ImRs
Description: Imagery Rescripting regular
Study NCT00069160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
Study NCT01277601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 180 µg administered via subcutaneous injection once weekly
Study NCT01666626 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound stiffness imaging
Description: Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
Study NCT03898453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
Study NCT03898453 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: support psychotherapy
Description: Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques... Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
Study NCT04423991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COViage
Description: Machine learning intervention
Study NCT04828278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: Bonded Arginine Silicate
Study NCT04828278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT02635594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
Study NCT02635594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000mg cellulose + 475mg L-tartaric acid
Study NCT02621359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500 mg twice daily
Study NCT02621359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 500 mg once daily
Study NCT02621359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: Doxycyclin 100 mg twice daily
Study NCT02621359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg twice daily
Study NCT02332629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
Study NCT02332629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study NCT02059135 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human antithrombin (ATryn)
Description: Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
Study NCT02059135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: Placebo Comparator: Normal Saline 0.9%
Study NCT02523755 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Epidural analgesia Ropivacaine
Description: Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
Study NCT02523755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia Ropivacaine
Description: Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
Study NCT02523755 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Absence of epidural analgesia
Description: Measurement of regional distribution as assessed by EIT before and after delivery
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: 30 mg/m2/d for 5days
Study NCT02523755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absence of epidural analgesia
Description: Measurement of regional distribution as assessed by EIT before and after delivery
Study NCT04439929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUR01
Description: Administered as a single 40 mg, subcutaneous dose
Study NCT04439929 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab-EU
Description: Administered as a single 40 mg, subcutaneous dose
Study NCT04020666 — intervention group
Intervention type: DRUG
Intervention: Urinary Kallidinogenase
Study NCT02389829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Study NCT02389829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Study NCT02389829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Study NCT01580124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI alone
Description: PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
Study NCT01580124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + Defragmentation + linear lesions
Description: PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
Study NCT00563693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASV
Description: Adaptive servo ventilator
Study NCT00563693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without Autoset CS2
Description: without Autoset CS2
Study NCT00563693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without Autoset CS2
Description: without Autoset CS2
Study NCT02584101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: ACT therapy administered in 3 sessions over a 4 week period
Study NCT02584101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: 2 group discussion sessions over a 4 week period
Study NCT00450437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY CRM
Description: One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
Study NCT00450437 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY Conjugate vaccine
Description: One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
Study NCT02110082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urelumab
Study NCT02110082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-lymphocyte globulin
Description: 1.5-2 mg/kg/d for 4 days
Study NCT02461121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 40 mg/kg/d for 2 days
Study NCT01892748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
Study NCT01892748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
Study NCT02525107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: SCD patients on Hydroxyurea
Study NCT02525107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SCD patients on Hydroxyurea
Study NCT02525107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 capsules
Description: SCD patients not on Hydroxyurea
Study NCT02525107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SCD patients not on Hydroxyurea
Study NCT02830594 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo palliative external beam radiation therapy
Study NCT02830594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02830594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01476215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol fast dissolution suspension
Study NCT01476215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol medium dissolution suspension
Study NCT01476215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol slow dissolution suspension
Study NCT01476215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02167828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Study NCT04575428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve block
Description: Percutaneous splanchnic nerve block
Study NCT00337714 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVC impregnated with silver nanoparticles (AgTive®)
Description: insertion of medicated silver nanoparticles CVC
Study NCT00337714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CVC cannulation
Description: placement of conventional trilumen CVCs
Study NCT02001727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 13C-Urea breath test for Helicobacter Pylori
Study NCT02001727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionaire
Study NCT02001727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionaire
Study NCT00069160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tariquidar
Description: Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
Study NCT00069160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi imaging
Description: Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
Study NCT05589428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low sodium bread
Description: Bread low in sodium
Study NCT05589428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal bread from bakery
Study NCT01099280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNPITAN FORT 5 IU
Description: A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
Study NCT01099280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propess,SYNPITAN FORT
Description: a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
Study NCT01957631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (Bupivacaine and Depo Medrol)
Description: The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
Study NCT01957631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: 10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
Study NCT03972748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
Study NCT03560401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knight-Taylor [chairback] brace
Description: Knight-Taylor \[chairback\] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
Study NCT02620293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eczema Repair Emollient
Description: An Emollient
Study NCT03218995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eteplirsen
Description: Infusion for intravenous use.
Study NCT05352620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant assisted maxillary overdenture
Description: For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
Study NCT04126538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone capsule
Description: In the patient group, pirfenidone capsule was taken orally once for 400mg
Study NCT04126538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirfenidone capsule
Description: Healthy subjects took pirfenidone capsule 400mg once orally
Study NCT01238159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT+MIDLE chemotherapy
Description: Patients are planned to be treated with CCRT plus MIDLE chemotherapy
Study NCT01981460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue and light treatment
Description: Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
Study NCT04253418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano-Pulse Stimulation (NPS)
Description: Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.
Study NCT01123811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab IF
Description: Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
Study NCT02646995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified lipid formulation
Description: Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
Study NCT02646995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
Study NCT03634969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986224
Description: Specified dose on specified days
Study NCT02839538 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: Injection at perianal region with ropivacaine 0.75%(20ml)
Study NCT02839538 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subarachnoidal block
Description: Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
Study NCT04169269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
Description: anticoagulant, subcutaneous injection
Study NCT04169269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 milligram Oral Tablet
Description: anticoagulant, oral
Study NCT02154607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2-Laser Treatment
Study NCT01343043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(c259)T Cells
Description: Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
Study NCT00583349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, nanoparticle albumin-bound
Description: Intravesically administered, dose escalation, 6 weekly instillations
Study NCT02306473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Subjects will be challenged with inhaled mannitol according to already approved protocols.
Study NCT03966573 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiographic imaging
Description: Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
Study NCT03966573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating function
Description: Test function and physical capasity
Study NCT03966573 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Forms
Description: Forms for evaluating quality of life, pain, function
Study NCT06521788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-assisted breast ultrasound
Description: AI-assisted breast ultrasound in community-based breast cancer screening